Eli Lilly & Co (LLY) Tuesday announced that a Phase III study showed both Cialis and tamsulosin significantly improved scores on the International Prostate Symptom Score, compared to placebo, in men with signs and symptoms suggestive of benign prostatic hyperplasia, or BPH.
The randomized, double-blind, placebo-controlled, parallel-group, 12-week trial, conducted in 44 urology centers in 10 countries, assessed the efficacy and safety of Cialis 5 mg for daily use in parallel with tamsulosin 0.4 mg in men aged 45 years and older with signs and symptoms of BPH.
The company stated that Cialis improved erectile dysfunction in those men who had both signs and symptoms of BPH and ED.
The study also showed that maximum urinary flow rate increased significantly versus placebo with both Cialis and tamsulosin.
For comments and feedback: editorial@rttnews.com